GlassScriptPhysician profile
Tony Chuong
NPI 1922056803
$7,310.99
in general payments reported to CMS, 2019-2025
40 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $859 · 2021: $1,561 · 2022: $1,379 · 2023: $1,092 · 2024: $1,088 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.42 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,271.73 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $876.87 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $499.64 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $396.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $385.96 | 2019-2023 | Belsomra, Steglatro |
| Abbvie INC. | $375.31 | 2020-2025 | Creon, Linzess |
| Glaxosmithkline, LLC. | $368.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $351.57 | 2022-2025 | |
| Amgen INC. | $343.99 | 2019-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $288.83 | 2019-2022 | |
| Pfizer INC. | $256.44 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.29 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $199.43 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.44 | 2020-2023 | Xifaxan, Trulance |
| Exact Sciences Corporation | $171.00 | 2024-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Chuong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.